Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
07:00am, Monday, 01'st Dec 2025
LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering ne
Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?
12:37pm, Tuesday, 25'th Nov 2025
The U.K.'s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc's (NASDAQ: AUTL) Aucatzyl (obecabtagene autoleucel, or obe
LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programm
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline
10:28am, Friday, 14'th Nov 2025
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
04:05pm, Thursday, 13'th Nov 2025
LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering ne
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript
03:11pm, Wednesday, 12'th Nov 2025
Autolus Therapeutics plc ( AUTL ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Amanda Cray Christian Itin - CEO & Director Robert Dolski - Senior VP, CFO & Principal Accoun
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
07:00am, Wednesday, 12'th Nov 2025
Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data gener
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
12:25pm, Monday, 10'th Nov 2025
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
09:05am, Monday, 03'rd Nov 2025
LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering ne
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
07:00am, Thursday, 30'th Oct 2025
LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering nex
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
07:00am, Monday, 27'th Oct 2025
Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Pha
LONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering ne
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 15'th Oct 2025
LONDON and GAITHERSBURG, Md., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering ne
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
08:05am, Tuesday, 16'th Sep 2025
Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025.
Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable
05:26pm, Tuesday, 12'th Aug 2025
I remain bullish on Autolus Therapeutics as they advance their CAR T-cell therapy, obe-cel, in a competitive leukemia market. Obe-cel shows durable benefits, with 38% of responders at 33 months needin
